Limits...
Acute decompensated heart failure is routinely treated as a cardiopulmonary syndrome.

Dharmarajan K, Strait KM, Lagu T, Lindenauer PK, Tinetti ME, Lynn J, Li SX, Krumholz HM - PLoS ONE (2013)

Bottom Line: We focused on the receipt of medications appropriate for other acute conditions associated with shortness of breath including acute asthma, pneumonia, and exacerbated chronic obstructive pulmonary disease.We also calculated adjusted odds of in-hospital death, admission to the intensive care unit, and late intubation (intubation after hospital day 2).Respiratory treatment was more frequent among the 60,690 hospitalizations with chronic lung disease.

View Article: PubMed Central - PubMed

Affiliation: Division of Cardiology, Columbia University Medical Center, New York, New York, United States of America ; Center for Outcomes Research and Evaluation, Yale-New Haven Hospital, New Haven, Connecticut, United States of America.

ABSTRACT

Background: Heart failure as recognized and treated in typical practice may represent a complex condition that defies discrete categorizations. To illuminate this complexity, we examined treatment strategies for patients hospitalized and treated for decompensated heart failure. We focused on the receipt of medications appropriate for other acute conditions associated with shortness of breath including acute asthma, pneumonia, and exacerbated chronic obstructive pulmonary disease.

Methods and results: Using Premier Perspective(®), we studied adults hospitalized with a principal discharge diagnosis of heart failure and evidence of acute heart failure treatment from 2009-2010 at 370 US hospitals. We determined treatment with acute respiratory therapies during the initial 2 days of hospitalization and daily during hospital days 3-5. We also calculated adjusted odds of in-hospital death, admission to the intensive care unit, and late intubation (intubation after hospital day 2). Among 164,494 heart failure hospitalizations, 53% received acute respiratory therapies during the first 2 hospital days: 37% received short-acting inhaled bronchodilators, 33% received antibiotics, and 10% received high-dose corticosteroids. Of these 87,319 hospitalizations, over 60% continued receiving respiratory therapies after hospital day 2. Respiratory treatment was more frequent among the 60,690 hospitalizations with chronic lung disease. Treatment with acute respiratory therapy during the first 2 hospital days was associated with higher adjusted odds of all adverse outcomes.

Conclusions: Acute respiratory therapy is administered to more than half of patients hospitalized with and treated for decompensated heart failure. Heart failure is therefore regularly treated as a broader cardiopulmonary syndrome rather than as a singular cardiac condition.

Show MeSH

Related in: MedlinePlus

Longitudinal treatment pathways.A sample pathway is shown for a patient who receives treatment for heart failure and bronchodilators during the first 2 hospital days and acute respiratory treatment only during hospital days 3 through 5. Acute respiratory treatment includes treatment with short-acting inhaled bronchodilators, antibiotics, or corticosteroids. Within each time period, treatment groups are mutually exclusive and inclusive of all patients. HF, heart failure.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3824040&req=5

pone-0078222-g001: Longitudinal treatment pathways.A sample pathway is shown for a patient who receives treatment for heart failure and bronchodilators during the first 2 hospital days and acute respiratory treatment only during hospital days 3 through 5. Acute respiratory treatment includes treatment with short-acting inhaled bronchodilators, antibiotics, or corticosteroids. Within each time period, treatment groups are mutually exclusive and inclusive of all patients. HF, heart failure.

Mentions: We assigned admissions to 1 of 5 treatment groups based on respiratory medications of interest that were dispensed during the first 2 days of hospitalization. Treatment groups were structured around potential treatment regimens for acute asthma, pneumonia or exacerbated chronic obstructive pulmonary disease as described by clinical guidelines or found in common use [30–33]. Treatment groups were also mutually exclusive and exhaustive, meaning that all hospitalizations meeting study inclusion criteria were able to be categorized into 1 of these 5 groups. These 5 initial treatment groups were defined by the receipt of (1) heart failure treatment only; (2) heart failure treatment plus inhaled bronchodilators only; (3) heart failure treatment plus antibiotics with or without inhaled bronchodilators; (4) heart failure treatment plus corticosteroids with or without inhaled bronchodilators; and (5) heart failure treatment plus antibiotics and corticosteroids with or without inhaled bronchodilators (Figure 1).


Acute decompensated heart failure is routinely treated as a cardiopulmonary syndrome.

Dharmarajan K, Strait KM, Lagu T, Lindenauer PK, Tinetti ME, Lynn J, Li SX, Krumholz HM - PLoS ONE (2013)

Longitudinal treatment pathways.A sample pathway is shown for a patient who receives treatment for heart failure and bronchodilators during the first 2 hospital days and acute respiratory treatment only during hospital days 3 through 5. Acute respiratory treatment includes treatment with short-acting inhaled bronchodilators, antibiotics, or corticosteroids. Within each time period, treatment groups are mutually exclusive and inclusive of all patients. HF, heart failure.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3824040&req=5

pone-0078222-g001: Longitudinal treatment pathways.A sample pathway is shown for a patient who receives treatment for heart failure and bronchodilators during the first 2 hospital days and acute respiratory treatment only during hospital days 3 through 5. Acute respiratory treatment includes treatment with short-acting inhaled bronchodilators, antibiotics, or corticosteroids. Within each time period, treatment groups are mutually exclusive and inclusive of all patients. HF, heart failure.
Mentions: We assigned admissions to 1 of 5 treatment groups based on respiratory medications of interest that were dispensed during the first 2 days of hospitalization. Treatment groups were structured around potential treatment regimens for acute asthma, pneumonia or exacerbated chronic obstructive pulmonary disease as described by clinical guidelines or found in common use [30–33]. Treatment groups were also mutually exclusive and exhaustive, meaning that all hospitalizations meeting study inclusion criteria were able to be categorized into 1 of these 5 groups. These 5 initial treatment groups were defined by the receipt of (1) heart failure treatment only; (2) heart failure treatment plus inhaled bronchodilators only; (3) heart failure treatment plus antibiotics with or without inhaled bronchodilators; (4) heart failure treatment plus corticosteroids with or without inhaled bronchodilators; and (5) heart failure treatment plus antibiotics and corticosteroids with or without inhaled bronchodilators (Figure 1).

Bottom Line: We focused on the receipt of medications appropriate for other acute conditions associated with shortness of breath including acute asthma, pneumonia, and exacerbated chronic obstructive pulmonary disease.We also calculated adjusted odds of in-hospital death, admission to the intensive care unit, and late intubation (intubation after hospital day 2).Respiratory treatment was more frequent among the 60,690 hospitalizations with chronic lung disease.

View Article: PubMed Central - PubMed

Affiliation: Division of Cardiology, Columbia University Medical Center, New York, New York, United States of America ; Center for Outcomes Research and Evaluation, Yale-New Haven Hospital, New Haven, Connecticut, United States of America.

ABSTRACT

Background: Heart failure as recognized and treated in typical practice may represent a complex condition that defies discrete categorizations. To illuminate this complexity, we examined treatment strategies for patients hospitalized and treated for decompensated heart failure. We focused on the receipt of medications appropriate for other acute conditions associated with shortness of breath including acute asthma, pneumonia, and exacerbated chronic obstructive pulmonary disease.

Methods and results: Using Premier Perspective(®), we studied adults hospitalized with a principal discharge diagnosis of heart failure and evidence of acute heart failure treatment from 2009-2010 at 370 US hospitals. We determined treatment with acute respiratory therapies during the initial 2 days of hospitalization and daily during hospital days 3-5. We also calculated adjusted odds of in-hospital death, admission to the intensive care unit, and late intubation (intubation after hospital day 2). Among 164,494 heart failure hospitalizations, 53% received acute respiratory therapies during the first 2 hospital days: 37% received short-acting inhaled bronchodilators, 33% received antibiotics, and 10% received high-dose corticosteroids. Of these 87,319 hospitalizations, over 60% continued receiving respiratory therapies after hospital day 2. Respiratory treatment was more frequent among the 60,690 hospitalizations with chronic lung disease. Treatment with acute respiratory therapy during the first 2 hospital days was associated with higher adjusted odds of all adverse outcomes.

Conclusions: Acute respiratory therapy is administered to more than half of patients hospitalized with and treated for decompensated heart failure. Heart failure is therefore regularly treated as a broader cardiopulmonary syndrome rather than as a singular cardiac condition.

Show MeSH
Related in: MedlinePlus